Even now, after a decade of run-up, pharma’s readiness to implement and harness ISO IDMP standards still varies wildly, as does companies’ relative maturity in supporting
Respiratory diseases, common examples of which include asthma and chronic obstructive pulmonary disease (COPD), affect one in five people in the UK.1 The economic burden of these
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.